Hutchmed Limited Stock Fundamentals
| HMDCF Stock | USD 3.66 0.00 0.00% |
Fundamental analysis of HUTCHMED (China) allows traders to better anticipate movements in HUTCHMED (China)'s stock price by examining its financial health and performance throughout various phases of its business cycle.
HUTCHMED |
HUTCHMED Limited Company Profit Margin Analysis
HUTCHMED (China)'s Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current HUTCHMED (China) Profit Margin | (0.64) % |
Most of HUTCHMED (China)'s fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, HUTCHMED Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, HUTCHMED Limited has a Profit Margin of -0.6365%. This is 94.32% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The profit margin for all United States stocks is 49.88% lower than that of the firm.
HUTCHMED Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining HUTCHMED (China)'s current stock value. Our valuation model uses many indicators to compare HUTCHMED (China) value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across HUTCHMED (China) competition to find correlations between indicators driving HUTCHMED (China)'s intrinsic value. More Info.HUTCHMED Limited is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HUTCHMED (China)'s earnings, one of the primary drivers of an investment's value.HUTCHMED Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HUTCHMED (China)'s direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of HUTCHMED (China) could also be used in its relative valuation, which is a method of valuing HUTCHMED (China) by comparing valuation metrics of similar companies.HUTCHMED is currently under evaluation in profit margin category among its peers.
HUTCHMED Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.64) % | |||
| Operating Margin | (0.95) % | |||
| Current Valuation | 1.66 B | |||
| Shares Outstanding | 864.77 M | |||
| Shares Owned By Insiders | 44.52 % | |||
| Shares Owned By Institutions | 54.00 % | |||
| Price To Book | 3.03 X | |||
| Price To Sales | 6.53 X | |||
| Revenue | 356.13 M | |||
| Gross Profit | (201.19 M) | |||
| EBITDA | (207.96 M) | |||
| Net Income | (194.65 M) | |||
| Cash And Equivalents | 829.71 M | |||
| Cash Per Share | 0.98 X | |||
| Current Ratio | 3.18 X | |||
| Book Value Per Share | 0.95 X | |||
| Cash Flow From Operations | (204.22 M) | |||
| Number Of Employees | 2.11 K | |||
| Beta | 0.9 | |||
| Market Capitalization | 3.24 B | |||
| Total Asset | 1.37 B | |||
| Net Asset | 1.37 B |
About HUTCHMED (China) Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HUTCHMED Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HUTCHMED (China) using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HUTCHMED Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2110 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in HUTCHMED Pink Sheet
HUTCHMED (China) financial ratios help investors to determine whether HUTCHMED Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HUTCHMED with respect to the benefits of owning HUTCHMED (China) security.